Skip to main content

Advertisement

SpringerLink
Log in

The GH1/IGF-1 axis polymorphisms and their impact on breast cancer development

  • Review Paper
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The growth hormone 1/insulin-like growth factor-1 (GH1/IGF-1) axis plays an essential role in the development of the breast by regulating cell proliferation, differentiation and apoptosis. Imbalances within this axis lead to an aberrant signalling and recent research has focussed on the overexpression of these growth factors and their involvement in breast cancer development. The increased understanding of the molecular mechanisms and signalling pathways connected to the GH1/IGF-1 axis has provided important insights into aetiology, prevention and therapy for breast cancer. However, to identify the contribution of the GH1/IGF-1 signalling pathway to cancer risk still remains a challenge since the results of various studies are controversial. Here, we discuss the influence of low-penetrance polymorphisms in the genes along the GH1/IGF-1 axis and their impact on hormone levels and cancer risk, especially breast cancer. We point out what is known about the effects of the variants and show how the interaction of genetic variants affects breast cancer risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108

    PubMed  Google Scholar 

  2. Hulka BS, Moorman PG (2001) Breast cancer: hormones and other risk factors. Maturitas 38:103–113; discussion 113–116

    Google Scholar 

  3. Key TJ, Verkasalo PK, Banks E (2001) Epidemiology of breast cancer. Lancet Oncol 2:133–140

    PubMed  CAS  Google Scholar 

  4. Balmain A, Gray J, Ponder B (2003) The genetics and genomics of cancer. Nat Genet 33(Suppl.):238–244

    PubMed  CAS  Google Scholar 

  5. Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, Easton DF, Evans C, Deacon J, Stratton MR (1999) Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 91:943–949

    PubMed  CAS  Google Scholar 

  6. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K (2000) Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343:78–85

    PubMed  CAS  Google Scholar 

  7. Antoniou AC, Pharoah PD, McMullan G, Day NE, Ponder BA, Easton D (2001) Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet Epidemiol 21:1–18

    PubMed  CAS  Google Scholar 

  8. Houlston RS, Peto J (2003) The future of association studies of common cancers. Hum Genet 112:434–435

    PubMed  Google Scholar 

  9. Collins FS, Brooks LD, Chakravarti A (1998) A DNA polymorphism discovery resource for research on human genetic variation. Genome Res 8:1229–1231

    PubMed  CAS  Google Scholar 

  10. Imyanitov EN, Togo AV, Hanson KP (2004) Searching for cancer-associated gene polymorphisms: promises and obstacles. Cancer Lett 204:3–14

    PubMed  CAS  Google Scholar 

  11. Syvanen AC (2001) Accessing genetic variation: genotyping single nucleotide polymorphisms. Nat Rev Genet 2:930–942

    PubMed  CAS  Google Scholar 

  12. LeRoith D, Roberts CT Jr (2003) The insulin-like growth factor system and cancer. Cancer Lett 195:127–137

    PubMed  CAS  Google Scholar 

  13. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE (2000) The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21:215–244

    PubMed  CAS  Google Scholar 

  14. Laban C, Bustin SA, Jenkins PJ (2003) The GH-IGF-I axis and breast cancer. Trends Endocrinol Metab 14:28–34

    PubMed  CAS  Google Scholar 

  15. Le Roith D, Bondy C, Yakar S, Liu JL, Butler A (2001) The somatomedin hypothesis: 2001. Endocr Rev 22:53–74

    PubMed  CAS  Google Scholar 

  16. Emerman JT, Leahy M, Gout PW, Bruchovsky N (1985) Elevated growth hormone levels in sera from breast cancer patients. Horm Metab Res 17:421–424

    PubMed  CAS  Google Scholar 

  17. Tornell J, Carlsson B, Pohjanen P, Wennbo H, Rymo L, Isaksson O (1992) High frequency of mammary adenocarcinomas in metallothionein promoter-human growth hormone transgenic mice created from two different strains of mice. J Steroid Biochem Mol Biol 43:237–242

    PubMed  CAS  Google Scholar 

  18. Kaulsay KK, Zhu T, Bennett W, Lee KO, Lobie PE (2001) The effects of autocrine human growth hormone (hGH) on human mammary carcinoma cell behavior are mediated via the hGH receptor. Endocrinology 142:767–777

    PubMed  CAS  Google Scholar 

  19. Mukhina S, Mertani HC, Guo K, Lee KO, Gluckman PD, Lobie PE (2004) Phenotypic conversion of human mammary carcinoma cells by autocrine human growth hormone. Proc Natl Acad Sci USA 101:15166–15171

    PubMed  CAS  Google Scholar 

  20. Butler AA, Le Roith D (2001) Control of growth by the somatropic axis: growth hormone and the insulin-like growth factors have related and independent roles. Annu Rev Physiol 63:141–164

    PubMed  CAS  Google Scholar 

  21. Kiaris H, Schally AV, Kalofoutis A (2005) Extrapituitary effects of the growth hormone-releasing hormone. Vitam Horm 70:1–24

    PubMed  CAS  Google Scholar 

  22. Cassoni P, Papotti M, Ghe C, Catapano F, Sapino A, Graziani A, Deghenghi R, Reissmann T, Ghigo E, Muccioli G (2001) Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines. J Clin Endocrinol Metab 86:1738–1745

    PubMed  CAS  Google Scholar 

  23. Yang XF, Beamer WG, Huynh H, Pollak M (1996) Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation. Cancer Res 56:1509–1511

    PubMed  CAS  Google Scholar 

  24. Hejna M, Schmidinger M, Raderer M (2002) The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? Ann Oncol 13:653–668

    PubMed  CAS  Google Scholar 

  25. Lin-Su K, Wajnrajch MP (2002) Growth hormone releasing hormone (GHRH) and the GHRH receptor. Rev Endocr Metab Disord 3:313–323

    PubMed  CAS  Google Scholar 

  26. Schally AV, Varga JL (1999) Antagonistic analogs of growth hormone-releasing hormone: new potential antitumor agents. Trends Endocrinol Metab 10:383–391

    PubMed  CAS  Google Scholar 

  27. Mauras N, Haymond MW (2005) Are the metabolic effects of GH and IGF-I separable? Growth Horm IGF Res 15:19–27

    PubMed  CAS  Google Scholar 

  28. Pollak MN, Schernhammer ES, Hankinson SE (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4:505–518

    PubMed  CAS  Google Scholar 

  29. Fletcher O, Gibson L, Johnson N, Altmann DR, Holly JM, Ashworth A, Peto J, Silva Idos S (2005) Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: a systematic review. Cancer Epidemiol Biomarkers Prev 14:2–19

    PubMed  CAS  Google Scholar 

  30. Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363:1346–1353

    PubMed  CAS  Google Scholar 

  31. Shi R, Yu H, McLarty J, Glass J (2004) IGF-I and breast cancer: a meta-analysis. Int J Cancer 111:418–423

    PubMed  CAS  Google Scholar 

  32. Sugumar A, Liu YC, Xia Q, Koh YS, Matsuo K (2004) Insulin-like growth factor (IGF)-I and IGF-binding protein 3 and the risk of premenopausal breast cancer: a meta-analysis of literature. Int J Cancer 111:293–297

    PubMed  CAS  Google Scholar 

  33. Renehan AG, Egger M, Minder C, O’Dwyer ST, Shalet SM, Zwahlen M (2005) IGF-I, IGF binding protein-3 and breast cancer risk: comparison of 3 meta-analyses. Int J Cancer 115:1006–1007; author reply 1008

    Google Scholar 

  34. Rinaldi S, Kaaks R, Zeleniuch-Jacquotte A, Arslan AA, Shore RE, Koenig KL, Dossus L, Riboli E, Stattin P, Lukanova A, Toniolo P (2005) Insulin-like growth factor-I, IGF binding protein-3, and breast cancer in young women: a comparison of risk estimates using different peptide assays. Cancer Epidemiol Biomarkers Prev 14:48–52

    PubMed  CAS  Google Scholar 

  35. Schernhammer ES, Holly JM, Hunter DJ, Pollak MN, Hankinson SE (2006) Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in the Nurses Health Study II. Endocr Relat Cancer 13:583–592

    PubMed  CAS  Google Scholar 

  36. dos Santos Silva I, Johnson N, De Stavola B, Torres-Mejia G, Fletcher O, Allen DS, Allen NE, Key TJ, Fentiman IS, Holly JM, Peto J (2006) The insulin-like growth factor system and mammographic features in premenopausal and postmenopausal women. Cancer Epidemiol Biomarkers Prev 15:449–455

    PubMed  CAS  Google Scholar 

  37. Reisine T, Bell GI (1995) Molecular biology of somatostatin receptors. Endocr Rev 16:427–442

    PubMed  CAS  Google Scholar 

  38. Smitha MC, Maggi M, Orlando C (2004) Somatostatin receptors in non-endocrine tumours. Dig Liver Dis 36(Suppl. 1):S78–S85

    PubMed  Google Scholar 

  39. Canzian F, McKay JD, Cleveland RJ, Dossus L, Biessy C, Boillot C, Rinaldi S, Llewellyn M, Chajes V, Clavel-Chapelon F, Tehard B, Chang-Claude J, Linseisen J, Lahmann PH, Pischon T, Trichopoulos D, Trichopoulou A, Zilis D, Palli D, Tumino R, Vineis P, Berrino F, Bueno-de-Mesquita HB, van Gils CH, Peeters PH, Pera G, Barricarte A, Chirlaque MD, Quiros JR, Larranaga N, Martinez-Garcia C, Allen NE, Key TJ, Bingham SA, Khaw KT, Slimani N, Norat T, Riboli E, Kaaks R (2005) Genetic variation in the growth hormone synthesis pathway in relation to circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3, and breast cancer risk: results from the European prospective investigation into cancer and nutrition study. Cancer Epidemiol Biomarkers Prev 14:2316–2325

    PubMed  CAS  Google Scholar 

  40. Wagner K, Hemminki K, Grzybowska E, Klaes R, Burwinkel B, Bugert P, Schmutzler RK, Wappenschmidt B, Butkiewicz D, Pamula J, Pekala W, Forsti A (2006) Polymorphisms in genes involved in GH1 release and their association with breast cancer risk. Carcinogenesis 27:1867–1875

    PubMed  CAS  Google Scholar 

  41. Skibola DR, Smith MT, Bracci PM, Hubbard AE, Agana L, Chi S, Holly EA (2005) Polymorphisms in ghrelin and neuropeptide Y genes are associated with non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 14:1251–1256

    PubMed  CAS  Google Scholar 

  42. Torrisani J, Bouisson M, Puente E, Capella G, Laurent-Puig P, Berger A, Vaysse N, Susini C, Buscail L (2001) Transcription of SST2 somatostatin receptor gene in human pancreatic cancer cells is altered by single nucleotide promoter polymorphism. Gastroenterology 120:200–209

    PubMed  CAS  Google Scholar 

  43. Mendlewicz J, Linkowski P, Kerkhofs M, Leproult R, Copinschi G, Van Cauter E (1999) Genetic control of 24-hour growth hormone secretion in man: a twin study. J Clin Endocrinol Metab 84:856–862

    PubMed  CAS  Google Scholar 

  44. Hasegawa Y, Fujii K, Yamada M, Igarashi Y, Tachibana K, Tanaka T, Onigata K, Nishi Y, Kato S, Hasegawa T (2000) Identification of novel human GH-1 gene polymorphisms that are associated with growth hormone secretion and height. J Clin Endocrinol Metab 85:1290–1295

    PubMed  CAS  Google Scholar 

  45. Le Marchand L, Donlon T, Seifried A, Kaaks R, Rinaldi S, Wilkens LR (2002) Association of a common polymorphism in the human GH1 gene with colorectal neoplasia. J Natl Cancer Inst 94:454–460

    PubMed  CAS  Google Scholar 

  46. Wagner JK, Eble A, Cogan JD, Prince MA, Phillips JA III, Mullis PE (1997) Allelic variations in the human growth hormone-1 gene promoter of growth hormone-deficient patients and normal controls. Eur J Endocrinol 137:474–481

    PubMed  CAS  Google Scholar 

  47. Giordano M, Marchetti C, Chiorboli E, Bona G, Momigliano Richiardi P (1997) Evidence for gene conversion in the generation of extensive polymorphism in the promoter of the growth hormone gene. Hum Genet 100:249–255

    PubMed  CAS  Google Scholar 

  48. Horan M, Millar DS, Hedderich J, Lewis G, Newsway V, Mo N, Fryklund L, Procter AM, Krawczak M, Cooper DN (2003) Human growth hormone 1 (GH1) gene expression: complex haplotype-dependent influence of polymorphic variation in the proximal promoter and locus control region. Hum Mutat 21:408–423

    PubMed  CAS  Google Scholar 

  49. Mulhall C, Hegele RA, Cao H, Tritchler D, Yaffe M, Boyd NF (2005) Pituitary growth hormone and growth hormone-releasing hormone receptor genes and associations with mammographic measures and serum growth hormone. Cancer Epidemiol Biomarkers Prev 14:2648–2654

    PubMed  CAS  Google Scholar 

  50. Giordano M, Godi M, Giacopelli F, Lessi M, Mellone S, Paracchini R, Petri A, Bellone J, Ravazzolo R, Bona G, Momigliano-Richiardi P (2006) A variation in a Pit-1 site in the growth hormone gene (GH1) promoter induces a differential transcriptional activity. Mol Cell Endocrinol 249:51–57

    PubMed  CAS  Google Scholar 

  51. Jones BK, Monks BR, Liebhaber SA, Cooke NE (1995) The human growth hormone gene is regulated by a multicomponent locus control region. Mol Cell Biol 15:7010–7021

    PubMed  CAS  Google Scholar 

  52. Wagner K, Hemminki K, Israelsson E, Grzybowska E, Klaes R, Chen B, Butkiewicz D, Pamula J, Pekala W, Forsti A (2005) Association of polymorphisms and haplotypes in the human growth hormone 1 (GH1) gene with breast cancer. Endocr Relat Cancer 12:917–928

    PubMed  CAS  Google Scholar 

  53. Pantel J, Machinis K, Sobrier ML, Duquesnoy P, Goossens M, Amselem S (2000) Species-specific alternative splice mimicry at the growth hormone receptor locus revealed by the lineage of retroelements during primate evolution. J Biol Chem 275:18664–18669

    PubMed  CAS  Google Scholar 

  54. Stallings-Mann ML, Ludwiczak RL, Klinger KW, Rottman F (1996) Alternative splicing of exon 3 of the human growth hormone receptor is the result of an unusual genetic polymorphism. Proc Natl Acad Sci USA 93:12394–12399

    PubMed  CAS  Google Scholar 

  55. Dos Santos C, Essioux L, Teinturier C, Tauber M, Goffin V, Bougneres P (2004) A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nat Genet 36:720–724

    PubMed  CAS  Google Scholar 

  56. Binder G, Baur F, Schweizer R, Ranke MB (2006) The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children. J Clin Endocrinol Metab 91:659–664

    PubMed  CAS  Google Scholar 

  57. Wagner K, Hemminki K, Grzybowska E, Bermejo JL, Butkiewicz D, Pamula J, Pekala W, Forsti A (2005) Polymorphisms in the growth hormone receptor: a case–control study in breast cancer. Int J Cancer 118:2903–2906

    Google Scholar 

  58. Harrela M, Koistinen H, Kaprio J, Lehtovirta M, Tuomilehto J, Eriksson J, Toivanen L, Koskenvuo M, Leinonen P, Koistinen R, Seppala M (1996) Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest 98:2612–2615

    PubMed  CAS  Google Scholar 

  59. Jernstrom H, Deal C, Wilkin F, Chu W, Tao Y, Majeed N, Hudson T, Narod SA, Pollak M (2001) Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev 10:377–384

    PubMed  CAS  Google Scholar 

  60. Jernstrom H, Chu W, Vesprini D, Tao Y, Majeed N, Deal C, Pollak M, Narod SA (2001) Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: implications for premenopausal breast cancer risk. Mol Genet Metab 72:144–154

    PubMed  CAS  Google Scholar 

  61. Rosen CJ, Kurland ES, Vereault D, Adler RA, Rackoff PJ, Craig WY, Witte S, Rogers J, Bilezikian JP (1998) Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab 83:2286–2290

    PubMed  CAS  Google Scholar 

  62. DeLellis K, Ingles S, Kolonel L, McKean-Cowdin R, Henderson B, Stanczyk F, Probst-Hensch NM (2003) IGF1 genotype, mean plasma level and breast cancer risk in the Hawaii/Los Angeles multiethnic cohort. Br J Cancer 88:277–282

    PubMed  CAS  Google Scholar 

  63. Wen W, Gao YT, Shu XO, Yu H, Cai Q, Smith JR, Zheng W (2005) Insulin-like growth factor-I gene polymorphism and breast cancer risk in Chinese women. Int J Cancer 113:307–311

    PubMed  CAS  Google Scholar 

  64. Giovannucci E, Haiman CA, Platz EA, Hankinson SE, Pollak MN, Hunter DJ (2002) Dinucleotide repeat in the insulin-like growth factor-I gene is not related to risk of colorectal adenoma. Cancer Epidemiol Biomarkers Prev 11:1509–1510

    PubMed  CAS  Google Scholar 

  65. Missmer SA, Haiman CA, Hunter DJ, Willett WC, Colditz GA, Speizer FE, Pollak MN, Hankinson SE (2002) A sequence repeat in the insulin-like growth factor-1 gene and risk of breast cancer. Int J Cancer 100:332–336

    PubMed  CAS  Google Scholar 

  66. Yu H, Li BD, Smith M, Shi R, Berkel HJ, Kato I (2001) Polymorphic CA repeats in the IGF-I gene and breast cancer. Breast Cancer Res Treat 70:117–122

    PubMed  CAS  Google Scholar 

  67. Peters DG, Kassam A, St Jean PL, Yonas H, Ferrell RE (1999) Functional polymorphism in the matrix metalloproteinase-9 promoter as a potential risk factor for intracranial aneurysm. Stroke 30:2612–2616

    PubMed  CAS  Google Scholar 

  68. Pearson CE, Edamura KN, Cleary JD (2005) Repeat instability: mechanisms of dynamic mutations. Nat Rev Genet 6:729–742

    PubMed  CAS  Google Scholar 

  69. Wagner K, Hemminki K, Israelsson E, Grzybowska E, Soderberg M, Pamula J, Pekala W, Zientek H, Mielzynska D, Siwinska E, Forsti A (2005) Polymorphisms in the IGF-1 and IGFBP3 promoter and the risk of breast cancer. Breast Cancer Res Treat 92:133–140

    PubMed  CAS  Google Scholar 

  70. Deal C, Ma J, Wilkin F, Paquette J, Rozen F, Ge B, Hudson T, Stampfer M, Pollak M (2001) Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab 86:1274–1280

    PubMed  CAS  Google Scholar 

  71. Schernhammer ES, Hankinson SE, Hunter DJ, Blouin MJ, Pollak MN (2003) Polymorphic variation at the -202 locus in IGFBP3: influence on serum levels of insulin-like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk. Int J Cancer 107:60–64

    PubMed  CAS  Google Scholar 

  72. Wang L, Habuchi T, Tsuchiya N, Mitsumori K, Ohyama C, Sato K, Kinoshita H, Kamoto T, Nakamura A, Ogawa O, Kato T (2003) Insulin-like growth factor-binding protein-3 gene -202 A/C polymorphism is correlated with advanced disease status in prostate cancer. Cancer Res 63:4407–4411

    PubMed  CAS  Google Scholar 

  73. Al-Zahrani A, Sandhu MS, Luben RN, Thompson D, Baynes C, Pooley KA, Luccarini C, Munday H, Perkins B, Smith P, Pharoah PD, Wareham NJ, Easton DF, Ponder BA, Dunning AM (2005) IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer. Hum Mol Genet 15:1–10

    Google Scholar 

  74. Canzian F, McKay JD, Cleveland RJ, Dossus L, Biessy C, Rinaldi S, Landi S, Boillot C, Monnier S, Chajes V, Clavel-Chapelon F, Tehard B, Chang-Claude J, Linseisen J, Lahmann PH, Pischon T, Trichopoulos D, Trichopoulou A, Zilis D, Palli D, Tumino R, Vineis P, Berrino F, Bueno-de-Mesquita HB, van Gils CH, Peeters PH, Pera G, Ardanaz E, Chirlaque MD, Quiros JR, Larranaga N, Martinez-Garcia C, Allen NE, Key TJ, Bingham SA, Khaw KT, Slimani N, Norat T, Riboli E, Kaaks R (2006) Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC study. Br J Cancer 94:299–307

    Google Scholar 

  75. Canzian F, McKay JD, Cleveland RJ, Dossus L, Biessy C, Rinaldi S, Landi S, Boillot C, Monnier S, Chajes V, Clavel-Chapelon F, Tehard B, Chang-Claude J, Linseisen J, Lahmann PH, Pischon T, Trichopoulos D, Trichopoulou A, Zilis D, Palli D, Tumino R, Vineis P, Berrino F, Bueno-de-Mesquita HB, van Gils CH, Peeters PH, Pera G, Ardanaz E, Chirlaque MD, Quiros JR, Larranaga N, Martinez-Garcia C, Allen NE, Key TJ, Bingham SA, Khaw KT, Slimani N, Norat T, Riboli E, Kaaks R (2006) Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC study. Br J Cancer 94:299–307

    PubMed  CAS  Google Scholar 

  76. Ren Z, Cai Q, Shu XO, Cai H, Li C, Yu H, Gao YT, Zheng W (2004) Genetic polymorphisms in the IGFBP3 gene: association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women. Cancer Epidemiol Biomarkers Prev 13:1290–1295

    PubMed  CAS  Google Scholar 

  77. Almind K, Bjorbaek C, Vestergaard H, Hansen T, Echwald S, Pedersen O (1993) Aminoacid polymorphisms of insulin receptor substrate-1 in non-insulin-dependent diabetes mellitus. Lancet 342:828–832

    PubMed  CAS  Google Scholar 

  78. Clausen JO, Hansen T, Bjorbaek C, Echwald SM, Urhammer SA, Rasmussen S, Andersen CB, Hansen L, Almind K, Winther K et al. (1995) Insulin resistance: interactions between obesity and a common variant of insulin receptor substrate-1. Lancet 346:397–402

    PubMed  CAS  Google Scholar 

  79. Imai Y, Fusco A, Suzuki Y, Lesniak MA, D’Alfonso R, Sesti G, Bertoli A, Lauro R, Accili D, Taylor SI (1994) Variant sequences of insulin receptor substrate-1 in patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 79:1655–1658

    PubMed  CAS  Google Scholar 

  80. Slattery ML, Samowitz W, Curtin K, Ma KN, Hoffman M, Caan B, Neuhausen S (2004) Associations among IRS1, IRS2, IGF1, and IGFBP3 genetic polymorphisms and colorectal cancer. Cancer Epidemiol Biomarkers Prev 13:1206–1214

    PubMed  CAS  Google Scholar 

  81. Wagner K, Hemminki K, Grzybowska E, Klaes R, Butkiewicz D, Pamula J, Pekala W, Zientek H, Mielzynska D, Siwinska E, Forsti A (2004) The insulin-like growth factor-1 pathway mediator genes: SHC1 Met300Val shows a protective effect in breast cancer. Carcinogenesis 25:2473–2478

    PubMed  CAS  Google Scholar 

  82. Hunter DJ, Riboli E, Haiman CA, Albanes D, Altshuler D, Chanock SJ, Haynes RB, Henderson BE, Kaaks R, Stram DO, Thomas G, Thun MJ, Blanche H, Buring JE, Burtt NP, Calle EE, Cann H, Canzian F, Chen YC, Colditz GA, Cox DG, Dunning AM, Feigelson HS, Freedman ML, Gaziano JM, Giovannucci E, Hankinson SE, Hirschhorn JN, Hoover RN, Key T, Kolonel LN, Kraft P, Le Marchand L, Liu S, Ma J, Melnick S, Pharaoh P, Pike MC, Rodriguez C, Setiawan VW, Stampfer MJ, Trapido E, Travis R, Virtamo J, Wacholder S, Willett WC (2005) A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer 5:977–985

    PubMed  CAS  Google Scholar 

  83. Wong HL, Delellis K, Probst-Hensch N, Koh WP, Van Den Berg D, Lee HP, Yu MC, Ingles SA (2005) A new single nucleotide polymorphism in the insulin-like growth factor I regulatory region associates with colorectal cancer risk in Singapore Chinese. Cancer Epidemiol Biomarkers Prev 14:144–151

    PubMed  CAS  Google Scholar 

  84. Jerome L, Shiry L, Leyland-Jones B (2003) Deregulation of the IGF axis in cancer: epidemiological evidence and potential therapeutic interventions. Endocr Relat Cancer 10:561–578

    PubMed  CAS  Google Scholar 

  85. DeLellis K, Rinaldi S, Kaaks RJ, Kolonel LN, Henderson B, Le Marchand L (2004) Dietary and lifestyle correlates of plasma insulin-like growth factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3): the multiethnic cohort. Cancer Epidemiol Biomarkers Prev 13:1444–1451

    PubMed  CAS  Google Scholar 

  86. Slattery ML, Baumgartner KB, Byers T, Guiliano A, Sweeney C, Herrick J, Curtin K, Murtaugh M, Wolff R (2005) Genetic, anthropometric, and lifestyle factors associated with IGF-1 and IGFBP-3 levels in Hispanic and non-Hispanic white women. Cancer Causes Control 16:1147–1157

    PubMed  CAS  Google Scholar 

  87. Cleveland RJ, Gammon MD, Edmiston SN, Teitelbaum SL, Britton JA, Terry MB, Eng SM, Neugut AI, Santella RM, Conway K (2005) IGF1 CA repeat polymorphisms, lifestyle factors and breast cancer risk in the Long Island Breast Cancer Study Project. Carcinogenesis 27:758–765

    Google Scholar 

  88. Ren Z, Cai Q, Shu XO, Cai H, Cheng JR, Wen WQ, Gao YT, Zheng W (2004) Genetic polymorphisms in the human growth hormone-1 gene (GH1) and the risk of breast carcinoma. Cancer 101:251–257

    PubMed  CAS  Google Scholar 

  89. de Jong MM, Nolte IM, te Meerman GJ, van der Graaf WT, Oosterwijk JC, Kleibeuker JH, Schaapveld M, de Vries EG (2002) Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility. J Med Genet 39:225–242

    PubMed  Google Scholar 

  90. Adams EF, Symowski H, Buchfelder M, Poyner DR (2000) A polymorphism in the growth hormone (GH)-releasing hormone (GHRH) receptor gene is associated with elevated response to GHRH by human pituitary somatotrophinomas in vitro. Biochem Biophys Res Commun 275:33–36

    PubMed  CAS  Google Scholar 

  91. Vivenza D, Rapa A, Castellino N, Bellone S, Petri A, Vacca G, Aimaretti G, Broglio F, Bona G (2004) Ghrelin gene polymorphisms and ghrelin, insulin, IGF-I, leptin and anthropometric data in children and adolescents. Eur J Endocrinol 151:127–133

    PubMed  CAS  Google Scholar 

  92. Hinney A, Hoch A, Geller F, Schafer H, Siegfried W, Goldschmidt H, Remschmidt H, Hebebrand J (2002) Ghrelin gene: identification of missense variants and a frameshift mutation in extremely obese children and adolescents and healthy normal weight students. J Clin Endocrinol Metab 87:2716

    PubMed  CAS  Google Scholar 

  93. Ukkola O, Ravussin E, Jacobson P, Perusse L, Rankinen T, Tschop M, Heiman ML, Leon AS, Rao DC, Skinner JS, Wilmore JH, Sjostrom L, Bouchard C (2002) Role of ghrelin polymorphisms in obesity based on three different studies. Obes Res 10:782–791

    PubMed  CAS  Google Scholar 

  94. Larsen LH, Gjesing AP, Sorensen TI, Hamid YH, Echwald SM, Toubro S, Black E, Astrup A, Hansen T, Pedersen O (2005) Mutation analysis of the preproghrelin gene: no association with obesity and type 2 diabetes. Clin Biochem 38:420–424

    PubMed  CAS  Google Scholar 

  95. Ukkola O, Ravussin E, Jacobson P, Snyder EE, Chagnon M, Sjostrom L, Bouchard C (2001) Mutations in the preproghrelin/ghrelin gene associated with obesity in humans. J Clin Endocrinol Metab 86:3996–3999

    PubMed  CAS  Google Scholar 

  96. Korbonits M, Gueorguiev M, O’Grady E, Lecoeur C, Swan DC, Mein CA, Weill J, Grossman AB, Froguel P (2002) A variation in the ghrelin gene increases weight and decreases insulin secretion in tall, obese children. J Clin Endocrinol Metab 87:4005–4008

    PubMed  CAS  Google Scholar 

  97. Bing C, Ambye L, Fenger M, Jorgensen T, Borch-Johnsen K, Madsbad S, Urhammer SA (2005) Large-scale studies of the Leu72Met polymorphism of the ghrelin gene in relation to the metabolic syndrome and associated quantitative traits. Diabet Med 22:1157–1160

    PubMed  CAS  Google Scholar 

  98. Ukkola O, Kesaniemi YA (2003) Preproghrelin Leu72Met polymorphism in patients with type 2 diabetes mellitus. J Intern Med 254:391–394

    PubMed  CAS  Google Scholar 

  99. Wang HJ, Geller F, Dempfle A, Schauble N, Friedel S, Lichtner P, Fontenla-Horro F, Wudy S, Hagemann S, Gortner L, Huse K, Remschmidt H, Bettecken T, Meitinger T, Schafer H, Hebebrand J, Hinney A (2004) Ghrelin receptor gene: identification of several sequence variants in extremely obese children and adolescents, healthy normal-weight and underweight students, and children with short normal stature. J Clin Endocrinol Metab 89:157–162

    PubMed  CAS  Google Scholar 

  100. Vartiainen J, Poykko SM, Raisanen T, Kesaniemi YA, Ukkola O (2004) Sequencing analysis of the ghrelin receptor (growth hormone secretagogue receptor type 1a) gene. Eur J Endocrinol 150:457–463

    PubMed  CAS  Google Scholar 

  101. Carless MA, Curran JE, Gaffney P, Weinstein SR, Griffiths LR (2001) Association analysis of somatostatin receptor (SSTR1 and SSTR2) polymorphisms in breast cancer and solar keratosis. Cancer Lett 166:193–197

    PubMed  CAS  Google Scholar 

  102. Filopanti M, Ronchi C, Ballare E, Bondioni S, Lania AG, Losa M, Gelmini S, Peri A, Orlando C, Beck-Peccoz P, Spada A (2005) Analysis of somatostatin receptors 2 and 5 polymorphisms in patients with acromegaly. J Clin Endocrinol Metab 90:4824–4828

    PubMed  CAS  Google Scholar 

  103. Yamaguchi T, Maki K, Shibasaki Y (2001) Growth hormone receptor gene variant and mandibular height in the normal Japanese population. Am J Orthod Dentofacial Orthop 119:650–653

    PubMed  CAS  Google Scholar 

  104. Zhou J, Lu Y, Gao XH, Chen YC, Lu JJ, Bai YX, Shen Y, Wang BK (2005) The growth hormone receptor gene is associated with mandibular height in a Chinese population. J Dent Res 84:1052–1056

    Article  PubMed  CAS  Google Scholar 

  105. Figer A, Karasik YP, Baruch RG, Chetrit A, Papa MZ, Sade RB, Rizel S, Friedman E (2002) Insulin-like growth factor I polymorphism and breast cancer risk in Jewish women. Isr Med Assoc J 4:759–762

    PubMed  CAS  Google Scholar 

  106. Cleveland RJ, Gammon MD, Edmiston SN, Teitelbaum SL, Britton JA, Terry MB, Eng SM, Neugut AI, Santella RM, Conway K (2006) IGF1 CA repeat polymorphisms, lifestyle factors and breast cancer risk in the Long Island Breast Cancer Study Project. Carcinogenesis 27:758–765

    PubMed  CAS  Google Scholar 

  107. Jiang DK, Shen H, Li MX, Jiang C, Yang N, Zhu J, Wu Y, Qin YJ, Zhou Q, Deng HW (2005) No major effect of the insulin-like growth factor I gene on bone mineral density in premenopausal Chinese women. Bone 36:694–699

    PubMed  CAS  Google Scholar 

  108. Lai JH, Vesprini D, Zhang W, Yaffe MJ, Pollak M, Narod SA (2004) A polymorphic locus in the promoter region of the IGFBP3 gene is related to mammographic breast density. Cancer Epidemiol Biomarkers Prev 13:573–582

    PubMed  CAS  Google Scholar 

  109. Morimoto LM, Newcomb PA, White E, Bigler J, Potter JD (2005) Variation in plasma insulin-like growth factor-1 and insulin-like growth factor binding protein-3: genetic factors. Cancer Epidemiol Biomarkers Prev 14:1394–1401

    PubMed  CAS  Google Scholar 

  110. Slattery ML, Samowitz W, Hoffman M, Ma KN, Levin TR, Neuhausen S (2004) Aspirin, NSAIDs, and colorectal cancer: possible involvement in an insulin-related pathway. Cancer Epidemiol Biomarkers Prev 13:538–545

    PubMed  CAS  Google Scholar 

  111. Slattery ML, Murtaugh M, Caan B, Ma KN, Neuhausen S, Samowitz W (2005) Energy balance, insulin-related genes and risk of colon and rectal cancer. Int J Cancer 115:148–154

    PubMed  CAS  Google Scholar 

  112. Zecevic M, Amos CI, Gu X, Campos IM, Jones JS, Lynch PM, Rodriguez-Bigas MA, Frazier ML (2006) IGF1 gene polymorphism and risk for hereditary nonpolyposis colorectal cancer. J Natl Cancer Inst 98:139–143

    Article  PubMed  CAS  Google Scholar 

  113. Li L, Cicek MS, Casey G, Witte JS (2004) No association between genetic polymorphisms in IGF-I and IGFBP-3 and prostate cancer. Cancer Epidemiol Biomarkers Prev 13:497–498

    PubMed  Google Scholar 

  114. Schildkraut JM, Demark-Wahnefried W, Wenham RM, Grubber J, Jeffreys AS, Grambow SC, Marks JR, Moorman PG, Hoyo C, Ali S, Walther PJ (2005) IGF1 (CA)19 repeat and IGFBP3 -202 A/C genotypes and the risk of prostate cancer in Black and White men. Cancer Epidemiol Biomarkers Prev 14:403–408

    PubMed  CAS  Google Scholar 

  115. Friedrichsen DM, Hawley S, Shu J, Humphrey M, Sabacan L, Iwasaki L, Etzioni R, Ostrander EA, Stanford JL (2005) IGF-I and IGFBP-3 polymorphisms and risk of prostate cancer. Prostate 65:44–51

    PubMed  CAS  Google Scholar 

  116. Tsuchiya N, Wang L, Horikawa Y, Inoue T, Kakinuma H, Matsuura S, Sato K, Ogawa O, Kato T, Habuchi T (2005) CA repeat polymorphism in the insulin-like growth factor-I gene is associated with increased risk of prostate cancer and benign prostatic hyperplasia. Int J Oncol 26:225–231

    PubMed  CAS  Google Scholar 

  117. Vaessen N, Heutink P, Janssen JA, Witteman JC, Testers L, Hofman A, Lamberts SW, Oostra BA, Pols HA, van Duijn CM (2001) A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes 50:637–642

    PubMed  CAS  Google Scholar 

  118. Kato I, Eastham J, Li B, Smith M, Yu H (2003) Genotype–phenotype analysis for the polymorphic CA repeat in the insulin-like growth factor-I (IGF-I) gene. Eur J Epidemiol 18:203–209

    PubMed  CAS  Google Scholar 

  119. San Millan JL, Corton M, Villuendas G, Sancho J, Peral B, Escobar-Morreale HF (2004) Association of the polycystic ovary syndrome with genomic variants related to insulin resistance, type 2 diabetes mellitus, and obesity. J Clin Endocrinol Metab 89:2640–2646

    PubMed  CAS  Google Scholar 

  120. Cheng I, Stram DO, Penney KL, Pike M, Le Marchand L, Kolonel LN, Hirschhorn J, Altshuler D, Henderson BE, Freedman ML (2006) Common genetic variation in IGF1 and prostate cancer risk in the Multiethnic Cohort. J Natl Cancer Inst 98:123–134

    PubMed  CAS  Google Scholar 

  121. Setiawan VW, Cheng I, Stram DO, Penney KL, Le Marchand L, Altshuler D, Kolonel LN, Hirschhorn J, Henderson BE, Freedman ML (2006) Igf-I genetic variation and breast cancer: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev 15:172–174

    PubMed  CAS  Google Scholar 

  122. Sweeney C, Murtaugh MA, Baumgartner KB, Byers T, Giuliano AR, Herrick JS, Wolff R, Caan BJ, Slattery ML (2005) Insulin-like growth factor pathway polymorphisms associated with body size in Hispanic and non-Hispanic white women. Cancer Epidemiol Biomarkers Prev 14:1802–1809

    PubMed  CAS  Google Scholar 

  123. Moon JW, Chang YS, Ahn CW, Yoo KN, Shin JH, Kong JH, Kim YS, Chang J, Kim SK, Kim HJ, Kim SK (2005) Promoter -202 A/C polymorphism of insulin-like growth factor binding protein-3 gene and non-small cell lung cancer risk. Int J Cancer 118:353–356

    Google Scholar 

  124. Le Marchand L, Kolonel LN, Henderson BE, Wilkens LR (2005) Association of an exon 1 polymorphism in the IGFBP3 gene with circulating IGFBP-3 levels and colorectal cancer risk: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 14:1319–1321

    PubMed  CAS  Google Scholar 

  125. Sanchez-Corona J, Flores-Martinez SE, Machorro-Lazo MV, Galaviz-Hernandez C, Moran-Moguel MC, Perea FJ, Mujica-Lopez KI, Vargas-Ancona L, Laviada-Molina HA, Fernandez V, Pardio J, Arroyo P, Barrera H, Hanson RL (2004) Polymorphisms in candidate genes for type 2 diabetes mellitus in a Mexican population with metabolic syndrome findings. Diabetes Res Clin Pract 63:47–55

    PubMed  CAS  Google Scholar 

  126. Haap M, Machicao F, Stefan N, Thamer C, Tschritter O, Schnuck F, Wallwiener D, Stumvoll M, Haring HU, Fritsche A (2005) Genetic determinants of insulin action in polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 113:275–281

    PubMed  CAS  Google Scholar 

  127. Ehrmann DA, Tang X, Yoshiuchi I, Cox NJ, Bell GI (2002) Relationship of insulin receptor substrate-1 and -2 genotypes to phenotypic features of polycystic ovary syndrome. J Clin Endocrinol Metab 87:4297–4300

    PubMed  CAS  Google Scholar 

  128. Florez JC, Sjogren M, Burtt N, Orho-Melander M, Schayer S, Sun M, Almgren P, Lindblad U, Tuomi T, Gaudet D, Hudson TJ, Daly MJ, Ardlie KG, Hirschhorn JN, Altshuler D, Groop L (2004) Association testing in 9,000 people fails to confirm the association of the insulin receptor substrate-1 G972R polymorphism with type 2 diabetes. Diabetes 53:3313–3318

    PubMed  CAS  Google Scholar 

  129. van Dam RM, Hoebee B, Seidell JC, Schaap MM, Blaak EE, Feskens EJ (2004) The insulin receptor substrate-1 Gly972Arg polymorphism is not associated with Type 2 diabetes mellitus in two population-based studies. Diabet Med 21:752–758

    PubMed  Google Scholar 

  130. Laukkanen O, Pihlajamaki J, Lindstrom J, Eriksson J, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Tuomilehto J, Uusitupa M, Laakso M (2004) Common polymorphisms in the genes regulating the early insulin signalling pathway: effects on weight change and the conversion from impaired glucose tolerance to Type 2 diabetes. The Finnish Diabetes Prevention Study. Diabetologia 47:871–877

    PubMed  CAS  Google Scholar 

  131. ‘t Hart LM, Nijpels G, Dekker JM, Maassen JA, Heine RJ, van Haeften TW (2002) Variations in insulin secretion in carriers of gene variants in IRS-1 and -2. Diabetes 51:884–887

    PubMed  CAS  Google Scholar 

  132. Lei HH, Coresh J, Shuldiner AR, Boerwinkle E, Brancati FL (1999) Variants of the insulin receptor substrate-1 and fatty acid binding protein 2 genes and the risk of type 2 diabetes, obesity, and hyperinsulinemia in African-Americans: the Atherosclerosis Risk in Communities Study. Diabetes 48:1868–1872

    PubMed  CAS  Google Scholar 

  133. Koch M, Rett K, Volk A, Maerker E, Haist K, Deninger M, Renn W, Haring HU (1999) Amino acid polymorphism Gly 972 Arg in IRS-1 is not associated to lower clamp-derived insulin sensitivity in young healthy first degree relatives of patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 107:318–322

    Article  PubMed  CAS  Google Scholar 

  134. Ossei-Gerning N, Mansfield MW, Stickland MH, Grant PJ (1997) Insulin receptor substrate-1 gene polymorphism and cardiovascular risk in non-insulin dependent diabetes mellitus and patients undergoing coronary angiography. Clin Lab Haematol 19:123–128

    PubMed  CAS  Google Scholar 

  135. Laakso M, Malkki M, Kekalainen P, Kuusisto J, Deeb SS (1994) Insulin receptor substrate-1 variants in non-insulin-dependent diabetes. J Clin Invest 94:1141–1146

    PubMed  CAS  Google Scholar 

  136. Ito K, Katsuki A, Furuta M, Fujii M, Tsuchihashi K, Hori Y, Yano Y, Sumida Y, Adachi Y (1999) Insulin sensitivity is not affected by mutation of codon 972 of the human IRS-1 gene. Horm Res 52:230–234

    PubMed  CAS  Google Scholar 

  137. Shimokawa K, Kadowaki H, Sakura H, Otabe S, Hagura R, Kosaka K, Yazaki Y, Akanuma Y, Kadowaki T (1994) Molecular scanning of the glycogen synthase and insulin receptor substrate-1 genes in Japanese subjects with non-insulin-dependent diabetes mellitus. Biochem Biophys Res Commun 202:463–469

    PubMed  CAS  Google Scholar 

  138. Chuang LM, Lai CS, Yeh JI, Wu HP, Tai TY, Lin BJ (1996) No association between the Gly971Arg variant of the insulin receptor substrate 1 gene and NIDDM in the Taiwanese population. Diabetes Care 19:446–449

    PubMed  CAS  Google Scholar 

  139. Baroni MG, D’Andrea MP, Montali A, Pannitteri G, Barilla F, Campagna F, Mazzei E, Lovari S, Seccareccia F, Campa PP, Ricci G, Pozzilli P, Urbinati G, Arca M (1999) A common mutation of the insulin receptor substrate-1 gene is a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 19:2975–2980

    PubMed  CAS  Google Scholar 

  140. Rasmussen SK, Urhammer SA, Hansen T, Almind K, Moller AM, Borch-Johnsen K, Pedersen O (2000) Variability of the insulin receptor substrate-1, hepatocyte nuclear factor-1alpha (HNF-1alpha), HNF-4alpha, and HNF-6 genes and size at birth in a population-based sample of young Danish subjects. J Clin Endocrinol Metab 85:2951–2953

    PubMed  CAS  Google Scholar 

  141. Bezerra RM, de Castro V, Sales T, Passini R, Jr., Marba ST, Saad ST, Saad MJ (2002) The Gly972Arg polymorphism in insulin receptor substrate-1 is associated with decreased birth weight in a population-based sample of Brazilian newborns. Diabetes Care 25:550–553

    PubMed  CAS  Google Scholar 

  142. Mammarella S, Romano F, Di Valerio A, Creati B, Esposito DL, Palmirotta R, Capani F, Vitullo P, Volpe G, Battista P, Della Loggia F, Mariani-Costantini R, Cama A (2000) Interaction between the G1057D variant of IRS-2 and overweight in the pathogenesis of type 2 diabetes. Hum Mol Genet 9:2517–2521

    PubMed  CAS  Google Scholar 

  143. Stefan N, Kovacs P, Stumvoll M, Hanson RL, Lehn-Stefan A, Permana PA, Baier LJ, Tataranni PA, Silver K, Bogardus C (2003) Metabolic effects of the Gly1057Asp polymorphism in IRS-2 and interactions with obesity. Diabetes 52:1544–1550

    PubMed  CAS  Google Scholar 

  144. Almind K, Frederiksen SK, Bernal D, Hansen T, Ambye L, Urhammer S, Ekstrom CT, Berglund L, Reneland R, Lithell H, White MF, Van Obberghen E, Pedersen O (1999) Search for variants of the gene-promoter and the potential phosphotyrosine encoding sequence of the insulin receptor substrate-2 gene: evaluation of their relation with alterations in insulin secretion and insulin sensitivity. Diabetologia 42:1244–1249

    PubMed  CAS  Google Scholar 

  145. Fritsche A, Madaus A, Renn W, Tschritter O, Teigeler A, Weisser M, Maerker E, Machicao F, Haring H, Stumvoll M (2001) The prevalent Gly1057Asp polymorphism in the insulin receptor substrate-2 gene is not associated with impaired insulin secretion. J Clin Endocrinol Metab 86:4822–4825

    PubMed  CAS  Google Scholar 

  146. Bernal D, Almind K, Yenush L, Ayoub M, Zhang Y, Rosshani L, Larsson C, Pedersen O, White MF (1998) Insulin receptor substrate-2 amino acid polymorphisms are not associated with random type 2 diabetes among Caucasians. Diabetes 47:976–979

    PubMed  CAS  Google Scholar 

  147. D’Alfonso R, Marini MA, Frittitta L, Sorge R, Frontoni S, Porzio O, Mariani LM, Lauro D, Gambardella S, Trischitta V, Federici M, Lauro R, Sesti G (2003) Polymorphisms of the insulin receptor substrate-2 in patients with type 2 diabetes. J Clin Endocrinol Metab 88:317–322

    PubMed  CAS  Google Scholar 

  148. Wang H, Rissanen J, Miettinen R, Karkkainen P, Kekalainen P, Kuusisto J, Mykkanen L, Karhapaa P, Laakso M (2001) New amino acid substitutions in the IRS-2 gene in Finnish and Chinese subjects with late-onset type 2 diabetes. Diabetes 50:1949–1951

    PubMed  CAS  Google Scholar 

  149. Iwamoto K, Mori H, Okazawa H, Hashiramoto M, Kasuga M (2002) Identification of a single nucleotide polymorphism showing no insulin-mediated suppression of the promoter activity in the human insulin receptor substrate 2 gene. Diabetologia 45:1182–1195

    PubMed  CAS  Google Scholar 

  150. Almind K, Frederiksen SK, Ahlgren MG, Urhammer S, Hansen T, Clausen JO, Pedersen O (1998) Common amino acid substitutions in insulin receptor substrate-4 are not associated with Type II diabetes mellitus or insulin resistance. Diabetologia 41:969–974

    PubMed  CAS  Google Scholar 

  151. Mooijaart SP, van Heemst D, Schreuder J, van Gerwen S, Beekman M, Brandt BW, Eline Slagboom P, Westendorp RG (2004) Variation in the SHC1 gene and longevity in humans. Exp Gerontol 39:263–268

    PubMed  CAS  Google Scholar 

  152. Almind K, Ahlgren MG, Hansen T, Urhammer SA, Clausen JO, Pedersen O (1999) Discovery of a Met300Val variant in Shc and studies of its relationship to birth weight and length, impaired insulin secretion, insulin resistance, and type 2 diabetes mellitus. J Clin Endocrinol Metab 84:2241–2244

    PubMed  CAS  Google Scholar 

  153. Almind K, Inoue G, Pedersen O, Kahn CR (1996) A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transfection studies. J Clin Invest 97:2569–2575

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by the grants from State Committee for Scientific Research (PBZ-KBN-090 P05/02), a grant from EU (LSHC-CT-2004-503465) and Deutsche Krebshilfe.

Author information

Authors and Affiliations

  1. Division of Molecular Genetic Epidemiology C050, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, 69120, Heidelberg, Germany

    Kerstin Wagner, Kari Hemminki & Asta Försti

  2. Center of Family Medicine, Karolinska Institute, Huddinge, Sweden

    Kari Hemminki & Asta Försti

Authors
  1. Kerstin Wagner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kari Hemminki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Asta Försti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kerstin Wagner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wagner, K., Hemminki, K. & Försti, A. The GH1/IGF-1 axis polymorphisms and their impact on breast cancer development. Breast Cancer Res Treat 104, 233–248 (2007). https://doi.org/10.1007/s10549-006-9411-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-006-9411-9

Keywords

Search

Navigation